Bazuka Treatment Gel For Effective, Pain-Free Treatment and Removal of Verrucas and Warts. With Emery Board, 6g

Product Description Bazuka Treatment Gel is a clinically proven treatment for verrucas, warts, corns and calluses. Bazuka Treatment Gel is a once-daily treatment with no fuss or plasters necessary. The key ingredients, salicylic acid and lactic acid, gently soften and remove the infected skin tissue - helping to eliminate the virus. Bazuka Treatment Gel forms a water-resistant, protective barrier to help stop the further spread of painful verrucas and warts removing the need for plasters and verruca socks. Most of us will get a verruca or wart at least once in our life, usually before the age of 20. Delaying treatment can make them harder to get rid of and painful to touch, so identifying them and treating promptly is key. Suitable for use by adults, the elderly and children over 2 years. *Based on Nielsen IQ MAT value and unit sales 28.12.2024. Ingredients Active ingredients: Salicylic Acid 12.0% w/w, Lactic Acid 4.0% w/w, Also contains: Camphor, Pyroxylin, Ethanol, Ethyl Acetate Directions 1. SOAK & DRY: Soak the affected area in warm water for 2 to 3 minutes. Dry the area thoroughly, using your own towel to avoid spreading infection. 2. APPLY: Carefully apply a thin coating (one or two drops) of the gel to the top of the wart, verruca, corn or callus only. 3. PEEL OR PICK: The next evening, carefully peel or pick off the white patch of dried gel from the wart, verruca, corn or callus. Then repeat steps 1 and 2. 4. GENTLY RUB: Once every week, before applying fresh gel, gently rub the wart, verruca, corn or callus with the emery board provided or a pumice stone. For full directions, see the enclosed package leaflet. Safety Warning Do not use Bazuka Treatment Gel if you are allergic (hypersensitive) to any of the ingredients. Only use to treat warts, verrucas, corns and calluses. Do not use on the face, anogenital regions or in areas of folded skin. Not to be used by diabetics or individuals with impaired circulation. Not suitable for children under 2 years of age. Children under 12 years should be treated by an adult and treatment of infants under 2 years is not recommended. For full safety information, see the enclosed package leaflet. It is important that you read and follow the instructions provided on the packaging and in the leaflet provided with this product. Use of this product for purposes other than those described, may result in unexpected side effects and can render the product ineffective. If your condition worsens or you experience any side effects, stop use immediately, and consider seeking advice from a healthcare professional. Any side effects or unexpected occurrences related to use of this product should be reported using the company details on the packaging, or, in the case of a medicine, to the MHRA using the Yellow Card Scheme.